Sandra Poole's most recent trade in Travere Therapeutics Inc was a trade of 19,500 Stock option (right to buy) done . Disclosure was reported to the exchange on May 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Sandra E. Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra E. Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 6,500 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Sandra E. Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra E. Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 6,500 | 23,500 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Sandra E. Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 13,500 | 13,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra E. Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 4,500 | 17,000 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Sandra Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,000 | 12,500 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Sandra Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Sandra Poole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,000 | 9,500 (0%) | 0% | 0 | Common Stock |